King's College London

Research portal

The Future: Experimental Therapies for Renal Disease in Diabetes

Research output: Contribution to journalReview article

Standard

The Future : Experimental Therapies for Renal Disease in Diabetes. / Fouli, Georgia E.; Gnudi, Luigi.

In: Nephron, 01.01.2018.

Research output: Contribution to journalReview article

Harvard

Fouli, GE & Gnudi, L 2018, 'The Future: Experimental Therapies for Renal Disease in Diabetes', Nephron. https://doi.org/10.1159/000492825

APA

Fouli, G. E., & Gnudi, L. (Accepted/In press). The Future: Experimental Therapies for Renal Disease in Diabetes. Nephron. https://doi.org/10.1159/000492825

Vancouver

Fouli GE, Gnudi L. The Future: Experimental Therapies for Renal Disease in Diabetes. Nephron. 2018 Jan 1. https://doi.org/10.1159/000492825

Author

Fouli, Georgia E. ; Gnudi, Luigi. / The Future : Experimental Therapies for Renal Disease in Diabetes. In: Nephron. 2018.

Bibtex Download

@article{bec88f81bd724c3c967f553ed6059d61,
title = "The Future: Experimental Therapies for Renal Disease in Diabetes",
abstract = "Diabetic nephropathy is the commonest cause of end-stage renal disease and affects between 30 and 45{\%} of patients with diabetes mellitus. There is no cure for diabetic nephropathy and the current management of this condition includes glycaemic control, blockade of the renin-angiotensin aldosterone system and lifestyle changes. However, many patients eventually progress to end-stage renal disease. The exact pathogenesis of diabetic nephropathy is still being researched, and recent advances have led to the development of several novel potential therapeutic targets. There are a number of different experimental therapies that are currently being assessed. Generally, these can be separated into drugs targeting vasculature/haemodynamic effects, drugs targeting inflammation and drugs targeting oxidative stress. Drugs targeting the vasculature include Tie-2 activators, -sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists. Anti-inflammatory therapies include inflammatory cytokines inhibitors, pentoxifylline, as well as anti-transforming growth factor α/-epiregulin therapies. Finally, anti-oxidative stress therapies include nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitors and allopurinol. Many new trials are providing promising results and it is likely that some of these therapies will be available for clinical use within the next decade. This article will seek to outline the main advancements in each of these experimental therapies for diabetic nephropathy. Results: Abnormal vascular remodelling, inflammation and oxidative stress seem to be the 3 main sources from which future new drugs for diabetic kidney disease will originate.",
author = "Fouli, {Georgia E.} and Luigi Gnudi",
year = "2018",
month = "1",
day = "1",
doi = "10.1159/000492825",
language = "English",
journal = "NEPHRON JOURNALS",
issn = "1660-8151",
publisher = "S. Karger AG",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - The Future

T2 - Experimental Therapies for Renal Disease in Diabetes

AU - Fouli, Georgia E.

AU - Gnudi, Luigi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Diabetic nephropathy is the commonest cause of end-stage renal disease and affects between 30 and 45% of patients with diabetes mellitus. There is no cure for diabetic nephropathy and the current management of this condition includes glycaemic control, blockade of the renin-angiotensin aldosterone system and lifestyle changes. However, many patients eventually progress to end-stage renal disease. The exact pathogenesis of diabetic nephropathy is still being researched, and recent advances have led to the development of several novel potential therapeutic targets. There are a number of different experimental therapies that are currently being assessed. Generally, these can be separated into drugs targeting vasculature/haemodynamic effects, drugs targeting inflammation and drugs targeting oxidative stress. Drugs targeting the vasculature include Tie-2 activators, -sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists. Anti-inflammatory therapies include inflammatory cytokines inhibitors, pentoxifylline, as well as anti-transforming growth factor α/-epiregulin therapies. Finally, anti-oxidative stress therapies include nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitors and allopurinol. Many new trials are providing promising results and it is likely that some of these therapies will be available for clinical use within the next decade. This article will seek to outline the main advancements in each of these experimental therapies for diabetic nephropathy. Results: Abnormal vascular remodelling, inflammation and oxidative stress seem to be the 3 main sources from which future new drugs for diabetic kidney disease will originate.

AB - Diabetic nephropathy is the commonest cause of end-stage renal disease and affects between 30 and 45% of patients with diabetes mellitus. There is no cure for diabetic nephropathy and the current management of this condition includes glycaemic control, blockade of the renin-angiotensin aldosterone system and lifestyle changes. However, many patients eventually progress to end-stage renal disease. The exact pathogenesis of diabetic nephropathy is still being researched, and recent advances have led to the development of several novel potential therapeutic targets. There are a number of different experimental therapies that are currently being assessed. Generally, these can be separated into drugs targeting vasculature/haemodynamic effects, drugs targeting inflammation and drugs targeting oxidative stress. Drugs targeting the vasculature include Tie-2 activators, -sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists. Anti-inflammatory therapies include inflammatory cytokines inhibitors, pentoxifylline, as well as anti-transforming growth factor α/-epiregulin therapies. Finally, anti-oxidative stress therapies include nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitors and allopurinol. Many new trials are providing promising results and it is likely that some of these therapies will be available for clinical use within the next decade. This article will seek to outline the main advancements in each of these experimental therapies for diabetic nephropathy. Results: Abnormal vascular remodelling, inflammation and oxidative stress seem to be the 3 main sources from which future new drugs for diabetic kidney disease will originate.

UR - http://www.scopus.com/inward/record.url?scp=85054146666&partnerID=8YFLogxK

U2 - 10.1159/000492825

DO - 10.1159/000492825

M3 - Review article

AN - SCOPUS:85054146666

JO - NEPHRON JOURNALS

JF - NEPHRON JOURNALS

SN - 1660-8151

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454